Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18518478 | 0.83 | CASP3 (0.45) | GAAMAPTHTTALDH1A1HSD17B10 | |
| SCHEMBL3580596 | 0.81 | GAA (0.38) | GAASMN1; SMN2RAB9AMAPTPOLB | |
| SCHEMBL3587299 | 0.81 | ALDH1A1 (0.38) | ALDH1A1KDM4ERXFP1 | |
| SCHEMBL3596407 | 0.80 | GAA (0.38) | GAASMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL4453709 | 0.79 | ALDH1A1 (0.46) | MAPTPOLBALDH1A1KDM4ERXFP1 | |
| SCHEMBL13072296 | 0.79 | GAA (0.40) | GAASMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL3589998 | 0.79 | GAA (0.40) | GAASMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL13712183 | 0.78 | HTT (0.40) | HTTRXFP1 | |
| SCHEMBL15724295 | 0.78 | KDM4E (0.37) | GAASMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL2960305 | 0.71 | ALPL (0.50) | GAASMN1; SMN2MAPTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | PEKARI KLAUS | 2010-12-23 | — | — | US | disclosed |
| US-7763728-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-07-27 | — | — | US | disclosed |
| US-7741488-B2 | Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer | 4SC AG (DE) | 2010-06-22 | — | — | US | disclosed |
| US-7714135-B2 | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714136-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090258873-A1 | Novel tetrahydropyridothiophenes | PEKARI KLAUS | 2009-10-15 | — | — | US | disclosed |
| US-20090257977-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | PEKARI KLAUS | 2009-10-15 | — | — | US | disclosed |
| US-20090252706-A1 | Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer | PEKARI KLAUS | 2009-10-08 | — | — | US | disclosed |
| US-20090227577-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | PEKARI KLAUS | 2009-09-10 | — | — | US | disclosed |
| US-20090098133-A1 | Tetrahydropyridothiophenes as Antiproliferative Agents for the Treatment of Cancer | ALTANA PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080096914-A1 | Tetrahydropyridothiophenes for the Treatment of Proliferative Diseases Such as Cancer | ALTANA PHARMA AG (DE) | 2008-04-24 | — | — | US | disclosed |
| EP-1896484-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1893618-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1851230-A1 | TETRAHYDROPYRIDOTHIOPHENES AS ANTRIPOLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2007-11-07 | — | — | EP | disclosed |
| EP-1851229-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | Nycomed GmbH (DE) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006125815-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006125813-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006084904-A1 | TETRAHYDROPYRIDOTHIOPHENES AS ANTRIPOLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006084869-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | NYCOMED GMBH (DE) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096914-A1 | Tetrahydropyridothiophenes for the Treatment of Proliferative Diseases Such as Cancer | MKI67, CCNT1, RB1 | GAA 3183/4885SMN1; SMN2 2960/4885RAB9A 1361/4885 |
| US-20090227577-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | CCNO, CCNY, CCNT1 | GAA 3566/4885SMN1; SMN2 4393/4885RAB9A 908/4885 |
| US-20090257977-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | BAX, BCL2, CCAR2 | GAA 4360/4885SMN1; SMN2 3283/4885RAB9A 1361/4885 |
| US-20090252706-A1 | Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer | RAB1A, RAB7A, RAB35 | GAA 1616/4885SMN1; SMN2 4845/4885RAB9A 19/4885 |
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | CCNT1, MALT1, CCNA1 | GAA 3288/4885SMN1; SMN2 4289/4885RAB9A 1252/4885 |
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | GAA 4321/4885SMN1; SMN2 3422/4885RAB9A 1221/4885 |
| US-20090098133-A1 | Tetrahydropyridothiophenes as Antiproliferative Agents for the Treatment of Cancer | MKI67, BCL2, BAX | GAA 3481/4885SMN1; SMN2 2882/4885RAB9A 1629/4885 |
| US-20090258873-A1 | Novel tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | GAA 4360/4885SMN1; SMN2 3283/4885RAB9A 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.